



David Gentien Platform Manager

TEAM GÉNOMIQUE

david.gentien@curie.fr



Key publications

Year of publication 2017

Roman Rouzier, Aurelie Roulot, Arthur H Jeiranian, Namratha Ram, Jean Marc Guinebretiere, Anne Vincent Salomon, David Gentien (2017 Jan 11)

Denaturing fixatives are compatible with the NanoString nCounter(®) platform and the Prosigna(®) assay.

New biotechnology : 37-41 : [DOI : S1871-6784\(16\)32312-3](https://doi.org/10.1016/j.celrep.2016.08.011)

Year of publication 2016

Alejandra Urrutia, Darragh Duffy, Vincent Rouilly, Céline Posseme, Raouf Djebali, Gabriel Illanes, Valentina Libri, Benoit Albaud, David Gentien, Barbara Piasecka, Milena Hasan, Magnus Fontes, Lluís Quintana-Murci, Matthew L Albert, (2016 Aug 30)

Standardized Whole-Blood Transcriptional Profiling Enables the Deconvolution of Complex Induced Immune Responses.

Cell reports : 2777-91 : [DOI : 10.1016/j.celrep.2016.08.011](https://doi.org/10.1016/j.celrep.2016.08.011)

Year of publication 2014

D Gentien, O Kosmider, F Nguyen-Khac, B Albaud, A Rapinat, A G Dumont, F Damm, T Popova, R Marais, M Fontenay, S Roman-Roman, O A Bernard, M-H Stern (2014 Jan 17)

A common alternative splicing signature is associated with SF3B1 mutations in malignancies from different cell lineages.

Leukemia : 1355-7 : [DOI : 10.1038/leu.2014.28](https://doi.org/10.1038/leu.2014.28)

Year of publication 2013

Simon J Furney, Malin Pedersen, David Gentien, Amaury G Dumont, Audrey Rapinat, Laurence Desjardins, Samra Turajlic, Sophie Piperno-Neumann, Pierre de la Grange, Sergio Roman-Roman, Marc-Henri Stern, Richard Marais (2013 Jul 16)

SF3B1 mutations are associated with alternative splicing in uveal melanoma.

Cancer discovery : 1122-9 : [DOI : 10.1158/2159-8290.CD-13-0330](https://doi.org/10.1158/2159-8290.CD-13-0330)